The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...
AstraZeneca said it plans to pump $2 billion in new investment into the U.S., one of the first major foreign companies to ...
AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...
AstraZeneca's China president Leon Wang, who was detained last month by Chinese authorities, is in touch with a lawyer but ...
Cambridge, England-based biopharmaceutical giant AstraZeneca is pouring billions of dollars into properties in the United ...
In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...
AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...
LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...
Eric Le Berrigaud, an analyst from Stifel Nicolaus, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price target remains the same with p14,100.00. Eric Le Berrigaud ...
Shares of AstraZeneca PLC AZN advanced 1.46% to £102.92 Thursday, on what proved to be an all-around positive trading ...